Given that functional impairment of PTEN is reported in up to 30% of all primary prostate cancers and that radical RT is a major treatment option for locally advanced high-risk disease, CXCR1/CXCR2-targeted therapeutics may have a significant impact across a large cohort of patients. This evidence concerns the gene CXCR2 and Familial prostate cancer.